↓ Skip to main content

Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study

Overview of attention for article published in Multiple Sclerosis Journal, January 2018
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (71st percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
10 X users

Citations

dimensions_citation
40 Dimensions

Readers on

mendeley
62 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study
Published in
Multiple Sclerosis Journal, January 2018
DOI 10.1177/1352458518754364
Pubmed ID
Authors

Damiano Baroncini, Mauro Zaffaroni, Lucia Moiola, Lorena Lorefice, Giuseppe Fenu, Pietro Iaffaldano, Marta Simone, Fulvia Fanelli, Francesco Patti, Emanuele D’Amico, Marco Capobianco, Antonio Bertolotto, Paolo Gallo, Monica Margoni, Silvia Miante, Nicoletta Milani, Maria Pia Amato, Isabella Righini, Paolo Bellantonio, Cinzia Scandellari, Gianfranco Costantino, Elio Scarpini, Roberto Bergamaschi, Giulia Mallucci, Giancarlo Comi, Angelo Ghezzi

Abstract

Few data are available on very long-term follow-up of pediatric multiple sclerosis (MS) patients treated with disease modifying treatments (DMTs). To present a long-term follow-up of a cohort of Pediatric-MS patients starting injectable first-line agents. Data regarding treatments, annualized relapse rate (ARR), Expanded Disability Status Scale (EDSS) score, and serious adverse event were collected. Baseline characteristics were tested in multivariate analysis to identify predictors of disease evolution. In total, 97 patients were followed for 12.5 ± 3.3 years. They started therapy at 13.9 ± 2.1 years, 88 with interferons and 9 with copaxone. During the whole follow-up, 82 patients changed therapy, switching to immunosuppressors/second-line treatment in 58% of cases. Compared to pre-treatment phase, the ARR was significantly reduced during the first treatment (from 3.2 ± 2.6 to 0.7 ± 1.5, p < 0.001), and it remained low during the whole follow-up (0.3 ± 0.2, p < 0.001). At last observation, 40% had disability worsening, but EDSS score remained <4 in 89%. One patient died at age of 23 years due to MS. One case of natalizumab-related progressive multifocal encephalopathy (PML) was recorded. Starting therapy before 12 years of age resulted in a better course of disease in multivariate analysis. Pediatric-MS patients benefited from interferons/copaxone, but the majority had to switch to more powerful drugs. Starting therapy before 12 years of age could lead to a more favorable outcome.

X Demographics

X Demographics

The data shown below were collected from the profiles of 10 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 62 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 62 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 14 23%
Other 7 11%
Student > Bachelor 4 6%
Student > Ph. D. Student 4 6%
Student > Master 4 6%
Other 11 18%
Unknown 18 29%
Readers by discipline Count As %
Medicine and Dentistry 18 29%
Neuroscience 15 24%
Biochemistry, Genetics and Molecular Biology 3 5%
Nursing and Health Professions 2 3%
Energy 1 2%
Other 3 5%
Unknown 20 32%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 March 2019.
All research outputs
#6,432,460
of 24,144,324 outputs
Outputs from Multiple Sclerosis Journal
#1,746
of 3,567 outputs
Outputs of similar age
#125,698
of 448,818 outputs
Outputs of similar age from Multiple Sclerosis Journal
#34
of 62 outputs
Altmetric has tracked 24,144,324 research outputs across all sources so far. This one has received more attention than most of these and is in the 73rd percentile.
So far Altmetric has tracked 3,567 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.1. This one has gotten more attention than average, scoring higher than 51% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 448,818 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.
We're also able to compare this research output to 62 others from the same source and published within six weeks on either side of this one. This one is in the 46th percentile – i.e., 46% of its contemporaries scored the same or lower than it.